Protagonist Therapeutics (PTGX) Capital Expenditures (2015 - 2026)
Protagonist Therapeutics (PTGX) posted Capital Expenditures of $110000.0 for Q1 2026, down 93.05% sequentially from $1.6 million in Q4 2025, and down 79.82% YoY from $545000.0 in Q1 2025.
Protagonist Therapeutics (PTGX) Capital Expenditures (2015 - 2026) Analysis & Trends
Protagonist Therapeutics has reported Capital Expenditures for 12 years, with the latest figure at $110000.0 in Q1 2026.
- Quarterly Capital Expenditures fell 79.82% year-over-year to $110000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 30.34% YoY) and the FY2025 annual result came in at $1.6 million, up 17.34% from the prior year.
- Capital Expenditures declined to $110000.0 in Q1 2026 per PTGX's latest filing, from $1.6 million in the prior quarter.
- Over five years, Capital Expenditures peaked at $1.6 million in Q4 2025 and troughed at -$502000.0 in Q3 2022.
- A 5-year average of $216647.1 and a median of $176000.0 in 2023 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2024 and 2025: Capital Expenditures jumped 2320.0% in 2024, then tumbled 1439.39% in 2025.
- Over 5 years, Capital Expenditures stood at -$42000.0 in 2022, then jumped by 145.24% to $19000.0 in 2023, then jumped by 1531.58% to $310000.0 in 2024, then jumped by 410.32% to $1.6 million in 2025, then tumbled by 93.05% to $110000.0 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $110000.0, $1.6 million, and -$95000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Protagonist Therapeutics | 10.03 Bn | 10.03 Bn | - | 617,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 617,000.00 |
| Jun 30, 2026 | 617,000.00 |
| Mar 31, 2026 | 110,000.00 |
| Mar 31, 2026 | 110,000.00 |
| Dec 31, 2025 | 1.58 Mn |
| Dec 31, 2025 | 1.58 Mn |
| Sep 30, 2025 | -95,000.00 |
| Sep 30, 2025 | -95,000.00 |
| Jun 30, 2025 | -442,000.00 |
| Jun 30, 2025 | -442,000.00 |
| Mar 31, 2025 | 545,000.00 |
| Mar 31, 2025 | 545,000.00 |
| Dec 31, 2024 | 310,000.00 |
| Dec 31, 2024 | 310,000.00 |
| Sep 30, 2024 | 770,000.00 |
| Sep 30, 2024 | 770,000.00 |
| Jun 30, 2024 | 33,000.00 |
| Jun 30, 2024 | 33,000.00 |
| Mar 31, 2024 | 242,000.00 |
| Mar 31, 2024 | 242,000.00 |